Scientific Papers

This article presents a compelling case for the development of an Epstein–Barr virus (EBV) vaccine, emphasizing the potential role of saponin-based adjuvants such as Matrix-M in enhancing vaccine [...]

This phase III open-label study evaluates the immunogenicity and safety of co-administering two adjuvanted vaccines: the AS01E-adjuvanted RSV prefusion F protein vaccine (Arexvy) and the [...]

This study introduces a novel, versatile liquid chromatography method coupled with charged aerosol detection (LC-CAD) for the reliable quantification and stability monitoring of QS-21, widely [...]

This paper introduces a novel, structure-based prion vaccine that effectively targets the infectious form of the prion protein (PrP^Sc) by mimicking its disease-specific surface features, [...]

This paper, closely related to the previous one, presents a novel platform for developing recombinant influenza vaccines using adjuvanted nanoliposomes that incorporate saponin-based adjuvants, [...]

This study presents a pioneering evaluation of QS-18, an abundant fraction from Quillaja saponaria, as a vaccine adjuvant within liposomal formulations for seasonal influenza. Traditionally, [...]

This paper provides a comprehensive analysis of the global supply chain for Quillaja-derived saponin adjuvants, notably QS-21, which are pivotal components in several recent and upcoming vaccines [...]

This original paper from Desert King provides a comprehensive evaluation of the scalability, sustainability, and supply capacity of QS-21, a highly potent saponin adjuvant derived from Quillaja [...]

The saponin QS-21, derived from Quillaja saponaria, has been clinically successful in vaccines due to its ability to elicit robust humoral and cellular immunity, exemplified by its inclusion in [...]

This research addresses the critical need to improve vaccine adjuvants, which are essential for enhancing immune responses in subunit vaccines. While AS01 has demonstrated potent [...]